AbbVie

Over its last 20 sessions ABBV has moved 1.38% on a typical day, making it a little calmer than most of the stocks Kinzan tracks (their median is 1.81%).

Today's move is well inside its normal range: +0.1σ, an entirely ordinary session.

It sits in the upper half of its 24-hour range of 283.39–286.13, measured on hourly closes.

Most of the move came in the London session (07:00–13:00 UTC), which accounted for about 66% of the day's price action.

Over the last 60 sessions of daily returns, it has moved most closely with JNJ (+0.70, a strong relationship), and most inversely to INTC (−0.48).

Its last close is at the 98th percentile of its own last 82 sessions, and its 20-day volatility at the 49th.

Market read: AbbVie is showing resilience, trading near the top of its range with steady New York interest.

What it is

AbbVie was separated from Abbott Laboratories in 2013, taking the research-based pharmaceutical business while Abbott kept devices, diagnostics and nutrition. For its first decade the company was defined by Humira, an injectable treatment for rheumatoid arthritis, psoriasis and inflammatory bowel disease that was for years the best-selling medicine in the world. Its largest growth products now are Skyrizi and Rinvoq, which treat many of the same immune conditions. The 2020 acquisition of Allergan added an aesthetics business built around Botox and dermal fillers, therapeutic Botox for conditions such as chronic migraine, and more neuroscience medicines. It also has oncology medicines, mainly for blood cancers.

What drives it

The company has lived through the patent cliff that most of its peers still face. Humira lost US exclusivity in 2023 when biosimilar copies launched, and the shares were judged for years on whether the newer immunology drugs could grow fast enough to absorb that loss. With the transition largely behind it, the questions have moved on: how long the successors can keep growing, when their own exclusivity runs out, and what the company buys next to extend the pipeline. Aesthetics behaves differently from the rest of the group. Patients mostly pay for it themselves, so it responds to consumer confidence, including in China, rather than to insurance coverage. US drug-pricing policy, including Medicare price negotiation, affects its older products. The dividend carries Abbott’s long record of annual increases and is a core part of the case for owning it.

How it trades through the day

Results come before the US open and the company usually updates full-year guidance each quarter, so the revision is read as closely as the quarter itself. Trading runs through the US cash session, 13:30 to 20:00 UTC in summer and 14:30 to 21:00 UTC in winter. Acquisitions and clinical setbacks have produced some of its largest single-day moves.

What it tends to move with

In immunology it is compared with Johnson & Johnson, Amgen and Bristol Myers Squibb, and it trades with the large pharmaceutical group and the healthcare sector more broadly. Its aesthetics arm gives it some sensitivity to consumer data that pure drug companies lack, and Galderma, the Swiss aesthetics specialist, offers a read during European hours.